Want to see JP:2796 full AI Analyst Report?
2796 Stock Chart & Stats
¥521.00
-¥5.00(-0.91%)
At close: 4:00 PM EST
¥521.00
-¥5.00(-0.91%)
Day’s Range― - ―
52-Week Range¥471.00 - ¥554.00
Previous CloseN/A
Volume3.80K
Average Volume (3M)7.43K
Market Cap
¥5.93B
Enterprise Value¥16.70K
Total Cash (Recent Filing)¥6.01B
Total Debt (Recent Filing)¥15.15B
Price to Earnings (P/E)60.0
Beta0.11
Next Earnings
Dec 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.76%
Share Statistics
EPS (TTM)10.04
Shares Outstanding12,060,381
10 Day Avg. Volume14,910
30 Day Avg. Volume7,433
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)0.85
Price to Sales (P/S)0.08
P/FCF Ratio2.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sustained increase in revenue demonstrates durable top-line expansion over several years, indicating continued demand for the company’s pharmacy and healthcare services. A growing revenue base can support operating scale, strengthen market reach, and provide more opportunity to improve earnings as the business develops.
Cash GenerationStrong recent operating and free cash flow shows that the business can convert operations into meaningful cash despite uneven reported earnings. This supports reinvestment, debt reduction, and financial flexibility, while suggesting underlying cash-generation capacity is more resilient than net income trends alone indicate.
Debt ReductionThe sharp reduction in debt materially improves financial flexibility and lowers the burden carried by future operating cash flow. Less leverage can reduce balance-sheet pressure, improve resilience during periods of earnings volatility, and give management greater capacity to allocate cash toward operations and growth.
Bears Say
Very Thin ProfitabilityA very small profit relative to revenue indicates that the company currently retains little earnings from each unit of sales. Thin profitability leaves limited protection against cost increases or changes in business mix and makes sustainable earnings improvement important for strengthening the company’s financial resilience.
Earnings VolatilityRepeated losses followed by only a modest return to profitability show that earnings have not yet demonstrated durable stability. This volatility can make internal funding less predictable, complicate long-term planning, and indicate that revenue growth has not consistently translated into dependable bottom-line performance.
Limited Equity CushionAlthough recent debt reduction is constructive, the relatively unchanged equity base provides limited evidence of a steadily expanding capital cushion. Combined with historically elevated leverage, this leaves the company more exposed to the effects of future earnings volatility and reduces balance-sheet capacity to absorb setbacks.
Pharmarise Holdings Corp. News
2796 FAQ
What was Pharmarise Holdings Corp.’s price range in the past 12 months?
Pharmarise Holdings Corp. lowest stock price was ¥471.00 and its highest was ¥554.00 in the past 12 months.
What is Pharmarise Holdings Corp.’s market cap?
Pharmarise Holdings Corp.’s market cap is ¥5.93B.
When is Pharmarise Holdings Corp.’s upcoming earnings report date?
Pharmarise Holdings Corp.’s upcoming earnings report date is Dec 17, 2026 which is in 76 days.
How were Pharmarise Holdings Corp.’s earnings last quarter?
Pharmarise Holdings Corp. released its earnings results on Sep 17, 2026. The company reported -¥3.2 earnings per share for the quarter.
Is Pharmarise Holdings Corp. overvalued?
According to Wall Street analysts Pharmarise Holdings Corp.’s price is currently Overvalued.
Does Pharmarise Holdings Corp. pay dividends?
Pharmarise Holdings Corp. pays a Annually dividend of ¥14 which represents an annual dividend yield of 2.76%. See more information on Pharmarise Holdings Corp. dividends here
What is Pharmarise Holdings Corp.’s EPS estimate?
Pharmarise Holdings Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmarise Holdings Corp. have?
Pharmarise Holdings Corp. has 12,060,381 shares outstanding.
What happened to Pharmarise Holdings Corp.’s price movement after its last earnings report?
Pharmarise Holdings Corp. reported an EPS of -¥3.2 in its last earnings report. Following the earnings report the stock price went up 1.782%.
Which hedge fund is a major shareholder of Pharmarise Holdings Corp.?
Currently, no hedge funds are holding shares in JP:2796
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharmarise Holdings Corp.
Pharmarise Holdings Corporation predominantly oversees a chain of pharmacies that dispense prescription medications throughout Japan. These establishments fulfill prescriptions provided by medical facilities, offering vital pharmaceutical services to patients. Beyond its primary dispensing activities, the company also manages drugstores and convenience stores, and retails cosmetic products. Additionally, it provides services including the safekeeping and administration of patient medical records for healthcare institutions, operates medical complex centers, and offers temporary staffing assistance. As of May 31, 2021, the corporation maintained a network of 347 outlets. Pharmarise Holdings Corporation was founded in 1984 and its main office is located in Tokyo, Japan.
Technical Analysis
Ohki Health Care Holdings, Inc.
―
Medical System Network Co., Ltd.
―
Shinnihonseiyaku Co., Ltd.
―
Chordia Therapeutics Inc.
―
Heartseed, Inc.
―